Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 8/2017

Open Access 01-08-2017 | Review Article

Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?

Authors: Giovanni Di Minno, David Navarro, Carlo Federico Perno, Mariana Canaro, Lutz Gürtler, James W. Ironside, Hermann Eichler, Andreas Tiede

Published in: Annals of Hematology | Issue 8/2017

Login to get access

Abstract

Patients with blood disorders (including leukaemia, platelet function disorders and coagulation factor deficiencies) or acute bleeding receive blood-derived products, such as red blood cells, platelet concentrates and plasma-derived products. Although the risk of pathogen contamination of blood products has fallen considerably over the past three decades, contamination is still a topic of concern. In order to counsel patients and obtain informed consent before transfusion, physicians are required to keep up to date with current knowledge on residual risk of pathogen transmission and methods of pathogen removal/inactivation. Here, we describe pathogens relevant to transfusion of blood products and discuss contemporary pathogen removal/inactivation procedures, as well as the potential risks associated with these products: the risk of contamination by infectious agents varies according to blood product/region, and there is a fine line between adequate inactivation and functional impairment of the product. The cost implications of implementing pathogen inactivation technology are also considered.
Literature
1.
Darby SC, Kan SW, Spooner RJ, Giangrande PL, Hill FG, Hay CR, Lee CA, Ludlam CA, Williams M (2007) Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 110(3):815–825. doi:10.​1182/​blood-2006-10-050435 CrossRefPubMed
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Harvey AR, Basavaraju SV, Chung KW, Kuehnert MJ (2015) Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. Transfusion 55(4):709–718. doi:10.​1111/​trf.​12918 CrossRefPubMed
14.
Dorsey KA, Moritz ED, Steele WR, Eder AF, Stramer SL (2013) A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010. Transfusion 53(6):1250–1256. doi:10.​1111/​j.​1537-2995.​2012.​03904.​x CrossRefPubMed
15.
16.
Hardwick J (2008) Blood processing. International Society of Blood Transfusion (ISBT) Science Series 3:148–176
17.
Patient.co.uk (2015) Blood Products for Transfusion
18.
19.
20.
Funk MB, Heiden M, Volkers P, Lohmann A, Keller-Stanislawski B (2015) Evaluation of risk minimisation measures for blood components - based on reporting rates of transfusion-transmitted reactions (1997-2013). Transfus med Hemother 42(4):240–246. doi:10.​1159/​000381996 CrossRefPubMedPubMedCentral
21.
Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ, German Red Cross NATSG (2008) Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 48(8):1558–1566. doi:10.​1111/​j.​1537-2995.​2008.​01718.​x CrossRefPubMed
22.
Velati C, Romano L, Fomiatti L, Baruffi L, Zanetti AR, Group SR (2008) Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey. Transfusion 48(10):2205–2213. doi:10.​1111/​j.​1537-2995.​2008.​01813.​x CrossRefPubMed
23.
Barjas-Castro ML, Angerami RN, Cunha MS, Suzuki A, Nogueira JS, Rocco IM, Maeda AY, Vasami FG, Katz G, Boin IF, Stucchi RS, Resende MR, Esposito DL, de Souza RP, da Fonseca BA, Addas-Carvalho M (2016) Probable transfusion-transmitted Zika virus in Brazil. Transfusion 56(7):1684–1688. doi:10.​1111/​trf.​13681 CrossRefPubMed
24.
25.
26.
27.
28.
29.
30.
EDQM (2010) European Committee (Partial Agreement) on Blood Transfusion (CD-P-TS). Symposium on implementation of pathogen reduction technologies for blood components—executive summary
31.
32.
33.
34.
Devine DV, Howe D (2010) Processing of whole blood into cellular components and plasma. International Society of Blood Transfusion (ISBT) Science Series 5:78–82
35.
36.
37.
Muller B, Walther-Wenke G, Kalus M, Alt T, Bux J, Zeiler T, Schottstedt V (2014) Routine bacterial screening of platelet concentrates by flow cytometry and its impact on product safety and supply. Vox Sang. doi:10.​1111/​vox.​12214
38.
39.
Kou YT, Pagotto F, Hannach B, Ramirez-Arcos S (2015) Fatal false-negative transfusion infection involving a buffy coat platelet pool contaminated with biofilm-positive Staphylococcus epidermidis: a case report. Transfusion 55(10):2384–2389. doi:10.​1111/​trf.​13154 CrossRefPubMed
40.
Chhabra P, Payne DC, Szilagyi PG, Edwards KM, Staat MA, Shirley SH, Wikswo M, Nix WA, Lu X, Parashar UD, Vinje J (2013) Etiology of viral gastroenteritis in children <5 years of age in the United States, 2008-2009. J Infect dis 208(5):790–800. doi:10.​1093/​infdis/​jit254 CrossRefPubMed
41.
42.
Zhang W, Li L, Deng X, Blumel J, Nubling CM, Hunfeld A, Baylis SA, Delwart E (2016) Viral nucleic acids in human plasma pools. Transfusion. doi:10.​1111/​trf.​13692
43.
44.
45.
46.
47.
48.
49.
50.
Lusher JM, Arkin S, Abildgaard CF, Schwartz RS (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. N Engl J med 328(7):453–459. doi:10.​1056/​NEJM199302183280​701 CrossRefPubMed
51.
52.
53.
54.
Jiang R, Monroe T, McRogers R, Larson PJ (2002) Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia 8(Suppl 2):1–5CrossRefPubMed
55.
Calizzani G, Profili S, Candura F, Lanzoni M, Vaglio S, Cannata L, Liumbruno GM, Franchini M, Mannucci PM, Grazzini G (2013) The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus 11(Suppl 4):s64–s76. doi:10.​2450/​2013.​011s PubMedPubMedCentral
56.
57.
Farcet MR, Lackner C, Antoine G, Rabel PO, Wieser A, Flicker A, Unger U, Modrof J, Kreil TR (2016) Hepatitis E virus and the safety of plasma products: investigations into the reduction capacity of manufacturing processes. Transfusion 56(2):383–391. doi:10.​1111/​trf.​13343 CrossRefPubMed
58.
Di Minno G, Perno CF, Tiede A, Navarro D, Canaro M, Guertler L, Ironside JW (2015) Current concepts in the prevention of pathogen transmission via blood/plasma-derived products for bleeding disorders. Blood rev. doi:10.​1016/​j.​blre.​2015.​07.​004
59.
Allain JP, Owusu-Ofori AK, Assennato SM, Marschner S, Goodrich RP, Owusu-Ofori S (2016) Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet 387(10029):1753–1761. doi:10.​1016/​S0140-6736(16)00581-X CrossRefPubMed
60.
Shepel M, Boyd J, Luider J, Gibb AP (2001) Interaction of Yersinia enterocolitica and Y. pseudotuberculosis with platelets. J med Microbiol 50(12):1030–1038CrossRefPubMed
61.
62.
63.
Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H (1991) Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60(4):207–213CrossRefPubMed
64.
65.
66.
67.
68.
Ciaravino V, McCullough T, Cimino G (2003) The role of toxicology assessment in transfusion medicine. Transfusion 43(10):1481–1492CrossRefPubMed
69.
70.
71.
72.
73.
74.
Knutson F, Osselaer J, Pierelli L, Lozano M, Cid J, Tardivel R, Garraud O, Hervig T, Domanovic D, Cukjati M, Gudmundson S, Hjalmarsdottir IB, Castrillo A, Gonzalez R, Brihante D, Santos M, Schlenke P, Elliott A, Lin JS, Tappe D, Stassinopoulos A, Green J, Corash L (2015) A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. Vox Sang 109(4):343–352. doi:10.​1111/​vox.​12287 CrossRefPubMedPubMedCentral
75.
76.
77.
78.
79.
80.
Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ, Dutch-Belgian Hcg (2010) Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 150(2):209–217. doi:10.​1111/​j.​1365-2141.​2010.​08227.​x PubMed
81.
Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, Corash L, Conlan MG, Group SS (2005) Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 45(12):1864–1875. doi:10.​1111/​j.​1537-2995.​2005.​00639.​x CrossRefPubMed
82.
83.
Corash L, Benjamin RJ (2016) The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: the amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion 56(Suppl 1):S29–S38. doi:10.​1111/​trf.​13530 CrossRefPubMed
84.
85.
Laughhunn A, Santa Maria F, Broult J, Lanteri MC, Stassinopoulos A, Musso D, Aubry M (2017) Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components. Transfusion. doi:10.​1111/​trf.​13993
86.
Winter KM, Johnson L, Kwok M, Vidovic D, Hyland RA, Mufti N, Erickson A, Marks DC (2014) Red blood cell in vitro quality and function is maintained after S-303 pathogen inactivation treatment. Transfusion 54(7):1798–1807. doi:10.​1111/​trf.​12545 CrossRefPubMed
87.
Cancelas JA, Gottschall JL, Rugg N, Graminske S, Schott MA, North A, Huang N, Mufti N, Erickson A, Rico S, Corash L (2017) Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study. Vox Sang. doi:10.​1111/​vox.​12500
88.
Abonnenc M, Sonego G, Crettaz D, Aliotta A, Prudent M, Tissot JD, Lion N (2015) In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfusion 55(9):2219–2230. doi:10.​1111/​trf.​13123 CrossRefPubMed
89.
Faddy HM, Fryk JJ, Prow NA, Watterson D, Young PR, Hall RA, Tolksdorf F, Sumian C, Gravemann U, Seltsam A, Marks DC (2016) Inactivation of dengue, chikungunya, and Ross River viruses in platelet concentrates after treatment with ultraviolet C light. Transfusion 56(6 Pt 2):1548–1555. doi:10.​1111/​trf.​13519 CrossRefPubMed
90.
Cap AP, Pidcoke HF, Keil SD, Staples HM, Anantpadma M, Carrion R Jr, Davey RA, Frazer-Abel A, Taylor AL, Gonzales R, Patterson JL, Goodrich RP (2016) Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro. Transfusion 56(Suppl 1):S6–15. doi:10.​1111/​trf.​13393 CrossRefPubMed
91.
92.
93.
Hellstern P, Sachse H, Schwinn H, Oberfrank K (1992) Manufacture and in vitro characterization of a solvent/detergent-treated human plasma. Vox Sang 63(3):178–185CrossRefPubMed
94.
95.
Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW (1992) Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 79(3):826–831PubMed
96.
Prince AM, Horowitz B, Brotman B (1986) Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1(8483):706–710CrossRefPubMed
97.
Lindholm PF, Annen K, Ramsey G (2011) Approaches to minimize infection risk in blood banking and transfusion practice. Infect Disord Drug Targets 11(1):45–56CrossRefPubMed
98.
99.
Lescoutra-Etchegaray N, Jaffre N, Sumian C, Durand V, Correia E, Mikol J, Luccantoni-Freire S, Culeux A, Deslys JP, Comoy EE (2015) Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update. Transfusion. doi:10.​1111/​trf.​12999
100.
101.
102.
Bougard D, Brandel JP, Belondrade M, Beringue V, Segarra C, Fleury H, Laplanche JL, Mayran C, Nicot S, Green A, Welaratne A, Narbey D, Fournier-Wirth C, Knight R, Will R, Tiberghien P, Haik S, Coste J (2016) Detection of prions in the plasma of presymptomatic and symptomatic patients with variant Creutzfeldt-Jakob disease. Sci Transl med 8(370):370ra182. doi:10.​1126/​scitranslmed.​aag1257 CrossRefPubMed
103.
104.
105.
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR (2016) A randomized trial of factor VIII and neutralizing antibodies in hemophilia a. N Engl J med 374(21):2054–2064. doi:10.​1056/​NEJMoa1516437 CrossRefPubMed
106.
Hashemi SM, Other J, Another C (2015) Risk for inhibitor development in severe hemophilia A is not associated with FVIII product class or with high von-Willebrand content—oral presentation at ISTH 2015
107.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Makipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM, PedNet, Group RS (2013) Factor VIII products and inhibitor development in severe hemophilia A. N Engl J med 368(3):231–239. doi:10.​1056/​NEJMoa1208024 CrossRefPubMed
108.
Piquet Y, Janvier G, Selosse P, Doutremepuich C, Jouneau J, Nicolle G, Platel D, Vezon G (1992) Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 63(4):251–256CrossRefPubMed
109.
Atance R, Pereira A, Ramirez B (2001) Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41(12):1548–1552CrossRefPubMed
110.
Barz D (1994) Detection of antigen structures in blood cells in various prepared plasma transfusions. Anaesthesiol Reanim 19(6):155–158PubMed
111.
Dewachter P, Castro S, Nicaise-Roland P, Chollet-Martin S, Le Beller C, Lillo-le-Louet A, Mouton-Faivre C (2011) Anaphylactic reaction after methylene blue-treated plasma transfusion. Br J Anaesth 106(5):687–689. doi:10.​1093/​bja/​aer009 CrossRefPubMed
112.
113.
Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121(5):778–785CrossRefPubMed
114.
Franchini M, Coppola A, Rocino A, Zanon E, Morfini M, Italian Association of Haemophilia Centers AWG, Accorsi A, Aru AB, Biasoli C, Cantori I, Castaman G, Cesaro S, Ciabatta C, De Cristofaro R, Delios G, Di Minno G, D’Inca M, Dragani A, Ettorre CP, Gagliano F, Gamba G, Gandini G, Giordano P, Giuffrida G, Gresele P, Latella C, Luciani M, Margaglione M, Marietta M, Mazzucconi MG, Messina M, Molinari AC, Notarangelo LD, Oliovecchio E, Peyvandi F, Piseddu G, Rossetti G, Rossi V, Santagostino E, Schiavoni M, Schinco P, Serino ML, Tagliaferri A, Testa S (2014) Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE survey. Haemophilia 20(2):e128–e135. doi:10.​1111/​hae.​12334 CrossRefPubMed
115.
116.
117.
Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G (2008) The chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 6(4):199–210PubMedPubMedCentral
118.
Pealer LN, Marfin AA, Petersen LR, Lanciotti RS, Page PL, Stramer SL, Stobierski MG, Signs K, Newman B, Kapoor H, Goodman JL, Chamberland ME, West Nile Virus Transmission Investigation T (2003) Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J med 349(13):1236–1245. doi:10.​1056/​NEJMoa030969 CrossRefPubMed
119.
Macciocchi D, Lanini S, Vairo F, Zumla A, Figueiredo LT, Lauria FN, Strada G, Brouqui P, Puro V, Krishna S, Kremsner P, Scognamiglio P, Kohler C, Nicastri E, Di Caro A, Cieri RM, Ioannidis JP, Kobinger G, Burattini MN, Ippolito G (2016) Short-term economic impact of the Zika virus outbreak. New Microbiol 39(4):287–289PubMed
120.
Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C (2011) A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 153(3):393–401. doi:10.​1111/​j.​1365-2141.​2011.​08635.​x CrossRefPubMed
121.
122.
123.
Girona-Llobera E, Jimenez-Marco T, Galmes-Trueba A, Muncunill J, Serret C, Serra N, Sedeno M (2014) Reducing the financial impact of pathogen inactivation technology for platelet components: our experience. Transfusion 54(1):158–168. doi:10.​1111/​trf.​12232 CrossRefPubMed
124.
125.
126.
McCullough J, Goldfinger D, Gorlin J, Riley WJ, Sandhu H, Stowell C, Ward D, Clay M, Pulkrabek S, Chrebtow V, Stassinopoulos A (2015) Cost implications of implementation of pathogen-inactivated platelets. Transfusion 55(10):2312–2320. doi:10.​1111/​trf.​13149 CrossRefPubMedPubMedCentral
127.
Kwon SY, Kim IS, Bae JE, Kang JW, Cho YJ, Cho NS, Lee SW (2014) Pathogen inactivation efficacy of Mirasol PRT system and intercept blood system for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sang 107(3):254–260. doi:10.​1111/​vox.​12158 CrossRefPubMed
128.
129.
130.
131.
Smit AK, Keogh LA, Hersch J, Newson AJ, Butow P, Williams G, Cust AE (2016) Public preferences for communicating personal genomic risk information: a focus group study. Health Expect 19(6):1203–1214. doi:10.​1111/​hex.​12406 CrossRefPubMed
132.
133.
Meybohm P, Richards T, Isbister J, Hofmann A, Shander A, Goodnough LT, Munoz M, Gombotz H, Weber CF, Choorapoikayil S, Spahn DR, Zacharowski K (2016) Patient blood management bundles to facilitate implementation. Transfus med rev. doi:10.​1016/​j.​tmrv.​2016.​05.​012
134.
Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A, Treatment Guidelines Working Group on Behalf of The World Federation Of H (2013) Guidelines for the management of hemophilia. Haemophilia 19(1):e1–47. doi:10.​1111/​j.​1365-2516.​2012.​02909.​x CrossRefPubMed
135.
136.
Rocino A, Coppola A, Franchini M, Castaman G, Santoro C, Zanon E, Santagostino E, Morfini M, Italian Association of Haemophilia Centres Working P (2014) Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 12(4):575–598. doi:10.​2450/​2014.​0223-14 PubMedPubMedCentral
137.
138.
139.
Hospital SEU (2015) Informed consent form for transfusion
140.
Friedman M, Arja W, Batra R, Daniel S, Hoehn D, Paniz AM, Selegean S, Slova D, Srivastava S, Vergara N (2012) Informed consent for blood transfusion: what do medicine residents tell? What do patients understand? Am J Clin Pathol 138(4):559–565. doi:10.​1309/​AJCP2TN5ODJLYGQR​ CrossRefPubMed
141.
142.
Vossoughi SR, Macauley R, Sazama K, Fung MK (2015) Attitudes, practices, and training on informed consent for transfusions and procedures: a survey of medical students and physicians. Am J Clin Pathol 144(2):315–321. doi:10.​1309/​AJCPP85EXSGZORYZ​ CrossRefPubMed
Metadata
Title
Pathogen reduction/inactivation of products for the treatment of bleeding disorders: what are the processes and what should we say to patients?
Authors
Giovanni Di Minno
David Navarro
Carlo Federico Perno
Mariana Canaro
Lutz Gürtler
James W. Ironside
Hermann Eichler
Andreas Tiede
Publication date
01-08-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-017-3028-4

Other articles of this Issue 8/2017

Annals of Hematology 8/2017 Go to the issue

Review Article

Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review

Original Article

Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden

Original Article

Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes

Original Article

Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT)

Original Article

Central nervous system involvement in adults with haemophagocytic lymphohistiocytosis: a single-center study

Original Article

Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits